BrightGene Bio Medical Technology C (688166) — Cash Flow Reinvestment Rate
BrightGene Bio Medical Technology C (688166) has a Cash Flow Reinvestment Rate of 3.77x as of June 2023, reinvesting CN¥100.56 Million (capex CN¥68.06 Million plus investments CN¥-32.50 Million) from operating cash flow of CN¥26.70 Million. See 688166 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
BrightGene Bio Medical Technology C Cash Flow Reinvestment Rate (2016–2024)
Historical reinvestment intensity for BrightGene Bio Medical Technology C across 9 annual periods. For the full cash flow conversion analysis, see how efficiently does BrightGene Bio Medical Technology C generate cash.
Annual Cash Flow Reinvestment Rate for BrightGene Bio Medical Technology C (2016–2024)
Year-by-year capital reinvestment analysis for BrightGene Bio Medical Technology C. See 688166 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.97x | CN¥484.23 Million | CN¥245.56 Million | CN¥257.20 Million | ▼ -54.0% |
| 2023 | 4.28x | CN¥834.53 Million | CN¥194.77 Million | CN¥389.33 Million | ▲ +51.5% |
| 2022 | 2.83x | CN¥880.11 Million | CN¥311.26 Million | CN¥726.73 Million | ▼ -45.8% |
| 2021 | 5.22x | CN¥918.30 Million | CN¥176.08 Million | CN¥909.66 Million | ▲ +41.3% |
| 2020 | 3.69x | CN¥573.73 Million | CN¥155.43 Million | CN¥355.27 Million | ▲ +44.9% |
| 2019 | 2.55x | CN¥156.20 Million | CN¥61.33 Million | CN¥89.54 Million | ▼ -23.5% |
| 2018 | 3.33x | CN¥213.01 Million | CN¥63.99 Million | CN¥112.47 Million | ▼ -35.4% |
| 2017 | 5.15x | CN¥184.24 Million | CN¥35.77 Million | CN¥83.70 Million | ▲ +109.3% |
| 2016 | 2.46x | CN¥73.16 Million | CN¥29.73 Million | CN¥36.58 Million | — |